

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 27, 2025

Capan-2

RRID:CVCL_0026

Type: Cell Line

Proper Citation

(RRID:CVCL_0026)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0026

Proper Citation: (RRID:CVCL_0026)

Sex: Male

Defining Citation: [PMID:1630814](#), [PMID:1764370](#), [PMID:3019537](#), [PMID:3518877](#), [PMID:6582512](#), [PMID:6935474](#), [PMID:7459858](#), [PMID:7809022](#), [PMID:7961102](#), [PMID:7972006](#), [PMID:8026879](#), [PMID:8194712](#), [PMID:8286197](#), [PMID:8426738](#), [PMID:10027410](#), [PMID:11169957](#), [PMID:11169959](#), [PMID:11668190](#), [PMID:12692724](#), [PMID:12800145](#), [PMID:14695172](#), [PMID:15126341](#), [PMID:15367885](#), [PMID:15688027](#), [PMID:15770730](#), [PMID:18298655](#), [PMID:18380791](#), [PMID:20037478](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20418756](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:24700732](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31037374](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Caution: TP53 mutation indicated incorrectly as being at c.818G>A in PubMed=1630814., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Proteome analysis by 2D-DE/MS., Omics: miRNA expression profiling., Omics: Metabolome analysis., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: Deep antibody staining analysis., Omics: Array-based CGH., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI RAS program mutant KRAS cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: Capan-2

Synonyms: CaPan-2, CAPAN-2, Capan 2, CAPAN 2, Capan2, CAPAN2

Cross References: BTO:BTO_0002745, CLO:CLO_0002198, EFO:EFO_0002154, MCCL:MCC:0000127, CLDB:cl642, CLDB:cl643, CLDB:cl644, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-80, BCRJ:0060, BioSample:SAMN03472025, BioSample:SAMN03473387, BioSample:SAMN10988212, cancercellines:CVCL_0026, CancerTools:161908, Cell_Model_Passport:SIDM00943, CGH-DB:163-1, CGH-DB:9270-4, ChEMBL-Cells:ChEMBL3308720, ChEMBL-Targets:ChEMBL1075417, CLS:300144, Cosmic:730527, Cosmic:736271, Cosmic:755303, Cosmic:808163, Cosmic:868246, Cosmic:910915, Cosmic:913303, Cosmic:922256, Cosmic:923167, Cosmic:932517, Cosmic:932987, Cosmic:933522, Cosmic:934554, Cosmic:947396, Cosmic:948727, Cosmic:949232, Cosmic:1006366, Cosmic:1108339, Cosmic:1299297, Cosmic:1320463, Cosmic:1366277, Cosmic:1571775, Cosmic:1995363, Cosmic:2009527, Cosmic:2046535, Cosmic:2434087, Cosmic:2668288, Cosmic-CLP:910915, DepMap:ACH-000107, DSMZ:ACC-245, DSMZCellDive:ACC-245, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:910915, GEO:GSM206453, GEO:GSM621896, GEO:GSM784710, GEO:GSM886921, GEO:GSM887987, GEO:GSM1024399, GEO:GSM1374440, GEO:GSM1669664, IARC_TP53:313, IARC_TP53:21042, IARC_TP53:30199, IGRhCellID:Capan2, IZSLER:BS TCL 10, KCLB:30080, LiGeA:CCELE_178, LINCS_LDP:LCL-1733, Lonza:1464, MetaboLights:MTBLS812, PharmacDB:Capan2_185_2019, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL_0026, PubChem_Cell_line:CVCL_0026, SKY/M-FISH/CGH:1993, Wikidata:Q54808591

ID: CVCL_0026

Record Creation Time: 20220427T215440+0000

Record Last Update: 20250420T104639+0000

Ratings and Alerts

No rating or validation information has been found for Capan-2.

No alerts have been found for Capan-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 261 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](https://fdilab.sci crunch.org).

Alors-Pérez E, et al. (2024) Spliceosomal dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets. *Molecular oncology*, 18(10), 2524.

Wehrli M, et al. (2024) Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(9), 1859.

Shrestha H, et al. (2024) The Janus kinase 1 is critical for pancreatic cancer initiation and progression. *Cell reports*, 43(5), 114202.

Ohara Y, et al. (2024) LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism. *Carcinogenesis*.

Moreno P, et al. (2024) ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. *bioRxiv : the preprint server for biology*.

Zhou Y, et al. (2024) Nudt21-mediated alternative polyadenylation of MZT1 3'UTR contributes to pancreatic cancer progression. *iScience*, 27(2), 108822.

Ohara Y, et al. (2024) ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer. *International journal of cancer*, 155(3), 569.

Ma X, et al. (2024) A programmable targeted protein-degradation platform for versatile applications in mammalian cells and mice. *Molecular cell*.

He C, et al. (2024) Vitamin B6 Competition in the Tumor Microenvironment Hampers Antitumor Functions of NK Cells. *Cancer discovery*, 14(1), 176.

Grze? M, et al. (2024) A common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer. *Cell death & disease*, 15(8), 638.

Xu M, et al. (2024) Tiliroside disrupted iron homeostasis and induced ferroptosis via directly targeting calpain-2 in pancreatic cancer cells. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 127, 155392.

Papacharisi E, et al. (2024) Novel Amanitin-based Antibody Drug Conjugates (ATAC®) targeting TROP2 for the treatment of Pancreatic Cancer. *Molecular cancer therapeutics*.

Long AW, et al. (2024) Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma. *Journal of hematology &*

oncology, 17(1), 20.

Bootsma S, et al. (2024) Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. *Cell reports. Medicine*, 5(5), 101523.

Dardare J, et al. (2024) DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparib. *Cell death discovery*, 10(1), 411.

Yamada T, et al. (2023) Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47? and immune checkpoint inhibitors. *Molecular therapy oncolytics*, 28, 31.

Zou X, et al. (2023) Characterization of Estrogen Receptors in Pancreatic Adenocarcinoma with Tertiary Lymphoid Structures. *Cancers*, 15(3).

Florio R, et al. (2023) Resveratrol Derivative Exhibits Marked Antiproliferative Actions, Affecting Stemness in Pancreatic Cancer Cells. *International journal of molecular sciences*, 24(3).

Wang L, et al. (2023) Exosome-transmitted hsa_circ_0012634 suppresses pancreatic ductal adenocarcinoma progression through regulating miR-147b/HIPK2 axis. *Cancer biology & therapy*, 24(1), 2218514.

Göbel T, et al. (2023) Three-dimensional growth reveals fine-tuning of 5-lipoxygenase by proliferative pathways in cancer. *Life science alliance*, 6(5).